Ten-year alcohol consumption typologies and trajectories of C-reactive protein, interleukin-6 and interleukin-1 receptor antagonist over the following 12 years: a prospective cohort study

Journal of Internal Medicine

Volumn 281, Issue 1, 2017, Pages 75-85

  Bell, S ^a   Mehta, G ^a   Moore, K ^a   Britton, A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

alcohol; cytokines; epidemiology; inflammation; longitudinal

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; NONOXINOL 9;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CHRONIC INFLAMMATION; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRINKING BEHAVIOR; FEMALE; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TIME TO TREATMENT; BLOOD; CORONARY DISEASE; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; RISK FACTOR;

ADULT; ALCOHOL DRINKING; C-REACTIVE PROTEIN; CORONARY DISEASE; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-6; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84994588903     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12544     Document Type: Article

References (71)

1. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ 2011; 342: d671.
2. Gémes K, Janszky I, Laugsand LE et al. Alcohol consumption is associated with a lower incidence of acute myocardial infarction: results from a large prospective population-based study in Norway. J Intern Med 2016; 279: 365–75.
3. Roerecke M, Rehm J. The cardioprotective association of average alcohol consumption and ischaemic heart disease: a systematic review and meta-analysis. Addiction 2012; 107: 1246–60.
4. Fekjær HO. Alcohol—a universal preventive agent? A critical analysis Addiction 2013; 108: 2051–7.
5. Mathews M, Liebenberg L, Mathews E. The mechanism by which moderate alcohol consumption influences coronary heart disease. Nutr J 2015; 14: 33.
6. Movva R, Figueredo VM. Alcohol and the heart: to abstain or not to abstain? Int J Cardiol 2013; 164: 267–76.
7. Brien SE, Ronksley PE, Turner BJ, Mukamal KJ, Ghali WA. Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies. BMJ 2011; 342: d636.
8. Holmes MV, Asselbergs FW, Palmer TM et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J 2014; 36: 539–50.
9. Barter PJ, Caulfield M, Eriksson M et al. Effects of Torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109–22.
10. Yaghootkar H, Lamina C, Scott RA et al. Mendelian randomisation studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. Diabetes 2013; 62: 3589–98.
11. Keavney B, Danesh J, Parish S et al. Fibrinogen and coronary heart disease: test of causality by “Mendelian randomization”. Int J Epidemiol 2006; 35: 935–43.
12. Sook Lee E, Park S, Kim E et al. Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. Int J Epidemiol 2013; 42: 1029–39.
13. Borges MC, Lawlor DA, de Oliveira C, White J, Horta B, Barros AJ. The role of Adiponectin in Coronary Heart Disease Risk: a Mendelian Randomization Study. Circ Res 2016; 119: 491–9.
14. Burgess S, Harshfield E. Mendelian randomization to assess causal effects of blood lipids on coronary heart disease: lessons from the past and applications to the future. Curr Opin Endocrinol Diabetes Obes 2016; 23: 124–30.
15. Imhof A, Koenig W. Alcohol inflammation and coronary heart disease. Addict Biol 2003; 8: 271–7.
16. The Emerging Risk Factors Collaboration. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012; 367: 1310–20.
17. Ansar W, Ghosh S. C-reactive protein and the biology of disease. Immunol Res 2013; 56: 131–42.
18. Kaptoge S, Seshasai SRK, Gao P et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J 2014; 35: 578–89.
19. Danesh J, Kaptoge S, Mann AG et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008; 5: e78.
20. IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012; 379: 1205–13.
21. Dinarello CA, Simon A, van der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012; 11: 633–52.
22. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity 2013; 39: 1003–18.
23. VanTassell BW, Toldo S, Mezzaroma E, Abbate A. Targeting interleukin-1 in heart disease. Circulation 2013; 128: 1910–23.
24. Witkin SS, Gerber S, Ledger WJ. Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis 2002; 34: 204–9.
25. Carstensen M, Herder C, Kivimäki M et al. Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes 2010; 59: 1222–7.
26. The Interleukin 1 Genetics Consortium. Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol 2015; 3: 243–53.
27. Chiva-Blanch G, Magraner E, Condines X et al. Effects of alcohol and polyphenols from beer on atherosclerotic biomarkers in high cardiovascular risk men: a randomized feeding trial. Nutr Metab Cardiovasc Dis 2015; 25: 36–45.
28. Stote KS, Tracy RP, Taylor PR, Baer DJ. The effect of moderate alcohol consumption on biomarkers of inflammation and hemostatic factors in postmenopausal women. Eur J Clin Nutr 2016; 70: 470–4.
29. Chiva-Blanch G, Urpi-Sarda M, Llorach R et al. Differential effects of polyphenols and alcohol of red wine on the expression of adhesion molecules and inflammatory cytokines related to atherosclerosis: a randomized clinical trial. Am J Clin Nutr 2012; 95: 326–34.
30. Imhof A, Woodward M, Doering A et al. Overall alcohol intake, beer, wine, and systemic markers of inflammation in western Europe: results from three MONICA samples (Augsburg, Glasgow, Lille). Eur Heart J 2004; 25: 2092–100.
31. Imhof A, Froehlich M, Brenner H, Boeing H, Pepys MB, Koenig W. Effect of alcohol consumption on systemic markers of inflammation. Lancet 2001; 357: 763–7.
32. Volpato S, Pahor M, Ferrucci L et al. Relationship of alcohol intake with inflammatory markers and plasminogen activator inhibitior-1 in well-functioning older adults: the Health, Aging, and Body Composition Study. Circulation 2004; 109: 607–12.
33. Marques-Vidal P, Bochud M, Bastardot F et al. Associations between alcohol consumption and selected cytokines in a Swiss population-based sample (CoLaus study). Atherosclerosis 2012; 222: 245–50.
34. Hamer M, Stamatakis E. The accumulative effects of modifiable risk factors on inflammation and haemostasis. Brain Behav Immun 2008; 22: 1041–3.
35. Britton A, Ben-Shlomo Y, Benzeval M, Kuh D, Bell S. Life course trajectories of alcohol consumption in the United Kingdom using longitudinal data from nine cohort studies. BMC Med 2015; 13: 47.
36. Britton A, Bell S. Reasons why people change their alcohol consumption in later life: findings from the Whitehall II Cohort Study. PLoS One 2015; 10: e0119421.
37. Britton A, Marmot MG, Shipley MJ. How does variability in alcohol consumption over time affect the relationship with mortality and coronary heart disease? Addiction 2010; 105: 639–45.
38. Greenfield TK, Kerr WC. Commentary on Liang & Chikritzhs (2011): quantifying the impacts of health problems on drinking and subsequent morbidity and mortality – life-course measures are essential. Addiction 2011; 106: 82–3.
39. Bell S, Britton A. The role of alcohol consumption in regulating circulating levels of adiponectin: a Prospective Cohort Study. J Clin Endocrinol Metab 2015; 100: 2763–8.
40. The Fibrinogen Studies Collaboration. Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27 247 adults in 15 prospective studies. Int J Epidemiol 2006; 35: 1570–8.
41. Knott C, Bell S, Britton A. Alcohol consumption and the risk of type 2 diabetes: a systematic review and dose-response meta-analysis of more than 1.9 million individuals from 38 observational studies. Diabetes Care 2015; 38: 1804–12.
42. Chikritzhs T, Stockwell T, Naimi T, Andreasson S, Dangardt F, Liang W. Has the leaning tower of presumed health benefits from “moderate” alcohol use finally collapsed? Addiction 2015; 110: 726–7.
43. Tabák AG, Kivimäki M, Brunner EJ et al. Changes in C-reactive protein levels before type 2 diabetes and cardiovascular death: the Whitehall II study. Eur J Endocrinol 2010; 163: 89–95.
44. Metti AL, Aizenstein H, Yaffe K et al. Trajectories of peripheral interleukin-6, structure of the hippocampus, and cognitive impairment over 14 years in older adults. Neurobiol Aging 2015; 36: 3038–44.
45. Janssen I, Landay AL, Ruppert K, Powell LH. Moderate wine consumption is associated with lower hemostatic and inflammatory risk factors over 8 years: the study of women's health across the nation (SWAN). Nutr Aging Amst Neth 2014; 2: 91.
46. Marmot M, Brunner E. Cohort Profile: the Whitehall II study. Int J Epidemiol 2005; 34: 251–6.
47. Britton A, O'Neill D, Bell S. Underestimating the alcohol content of a glass of wine: the implications for estimates of mortality risk. Alcohol Alcohol 2016; doi: 10.1093/alcalc/agw027 [Epub ahead of print].
48. Rehm J, Irving H, Ye Y, Kerr WC, Bond J, Greenfield TK. Are lifetime abstainers the best control group in alcohol epidemiology? On the stability and validity of reported lifetime abstention. Am J Epidemiol 2008; 168: 866–71.
49. Myers GL, Rifai N, Tracy RP et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the Laboratory Science Discussion Group. Circulation 2004; 110: e545–9.
50. Tabák AG, Carstensen M, Witte DR et al. Adiponectin trajectories before type 2 diabetes diagnosis: Whitehall II study. Diabetes Care 2012; 35: 2540–7.
51. Britton A, Marmot M. Different measures of alcohol consumption and risk of coronary heart disease and all-cause mortality: 11-year follow-up of the Whitehall II Cohort Study. Addiction 2004; 99: 109–16.
52. Bell S, Britton A. Drinking pattern during midlife and risk of developing depression during 28 years of follow-up: a prospective cohort study. Drug Alcohol Depend 2015; 155: 111–7.
53. The Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012; 379: 1214–24.
54. Muralidharan S, Ambade A, Fulham MA, Deshpande J, Catalano D, Mandrekar P. Moderate alcohol induces stress proteins HSF1 and hsp70 and inhibits proinflammatory cytokines resulting in endotoxin tolerance. J Immunol 2014; 193: 1975–87.
55. Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 2009; 30: 475–87.
56. Bala S, Marcos M, Gattu A, Catalano D, Szabo G. Acute binge drinking increases serum endotoxin and bacterial DNA levels in healthy individuals. PLoS One 2014; 9: e96864.
57. Vijay-Kumar M, Aitken JD, Carvalho FA et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-Like receptor 5. Science 2010; 328: 228–31.
58. Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761–72.
59. Reactive C, Protein Coronary Heart Disease Genetics Collaboration. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 2011; 342: d548.
60. Ng Fat L, Cable N, Shelton N. Worsening of health and a cessation or reduction in alcohol consumption to special occasion drinking across three decades of the life course. Alcohol Clin Exp Res 2015; 39: 166–74.
61. Leclercq S, De Saeger C, Delzenne N, de Timary P, Stärkel P. Role of inflammatory pathways, blood mononuclear cells, and gut-derived bacterial products in alcohol dependence. Biol Psychiatry 2014; 76: 725–33.
62. Pawelec G, Goldeck D, Derhovanessian E. Inflammation, ageing and chronic disease. Curr Opin Immunol 2014; 29: 23–8.
63. Dwarkasing J., Marks DL, Witkamp R., van Norren K. Hypothalamic inflammation and food intake regulation during chronic illness. Peptides 2016; 77: 60–6.
64. Verrill C, Markham H, Templeton A, Carr NJ, Sheron N. Alcohol-related cirrhosis—early abstinence is a key factor in prognosis, even in the most severe cases. Addiction 2009; 104: 768–74.
65. Powell WJ, Klatskin G. Duration of survival in patients with Laennec's cirrhosis: influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med 1968; 44: 406–20.
66. Naimi TS, Brown DW, Brewer RD et al. Cardiovascular risk factors and confounders among nondrinking and moderate-drinking U.S. adults. Am J Prev Med 2005; 28: 369–73.
67. Ng Fat L, Shelton N. Associations between self-reported illness and non-drinking in young adults. Addiction 2012; 107: 1612–20.
68. Rehm J, Shield KD, Roerecke M, Gmel G. Modelling the impact of alcohol consumption on cardiovascular disease mortality for comparative risk assessments: an overview. BMC Public Health 2016; 16: 1–9.
69. Bellis MA, Hughes K, Jones L et al. Holidays, celebrations, and commiserations: measuring drinking during feasting and fasting to improve national and individual estimates of alcohol consumption. BMC Med 2015; 13: 113.
70. Roerecke M, Rehm J. Alcohol consumption, drinking patterns, and ischemic heart disease: a narrative review of meta-analyses and a systematic review and meta-analysis of the impact of heavy drinking occasions on risk for moderate drinkers. BMC Med 2014; 12: 182.
71. Batty GD, Shipley M, Tabák A et al. Generalizability of occupational cohort study findings. Epidemiology 2014; 25: 932–3.